AllianceBernstein
NKTR icon

AllianceBernstein’s Nektar Therapeutics NKTR Stock Holding History

AllianceBernstein’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Buy
+36,000
New +$2.63M ﹤0.01% 1893
2025
Q2 		– Sell
-3,280
Closed -$33.5K – 3294
2025
Q1 		$33.5K Hold
3,280
– – ﹤0.01% 3162
2024
Q4 		$45.8K Hold
3,280
– – ﹤0.01% 3190
2024
Q3 		$64K Hold
3,280
– – ﹤0.01% 3173
2024
Q2 		$61K Buy
+3,280
New +$69.1K ﹤0.01% 3175
2023
Q2 		– Sell
-14,157
Closed -$149K – 3216
2023
Q1 		$149K Sell
14,157
-17,460
-55% -$528K ﹤0.01% 2970
2022
Q4 		$1.07M Sell
31,617
-51,040
-62% -$2.47M ﹤0.01% 2238
2022
Q3 		$3.97M Sell
82,657
-72,734
-47% -$4.33M ﹤0.01% 1510
2022
Q2 		$8.86M Buy
155,391
+89,410
+136% +$5.64M ﹤0.01% 1168
2022
Q1 		$5.33M Buy
65,981
+57,868
+713% +$8.56M ﹤0.01% 1553
2021
Q4 		$1.64M Sell
8,113
-10,348
-56% -$2.24M ﹤0.01% 2246
2021
Q3 		$4.97M Sell
18,461
-153
-0.8% -$36.8K ﹤0.01% 1611
2021
Q2 		$4.79M Sell
18,614
-266
-1% -$73.6K ﹤0.01% 1650
2021
Q1 		$5.66M Buy
18,880
+422
+2% +$131K ﹤0.01% 1487
2020
Q4 		$4.71M Sell
18,458
-366
-2% -$94.6K ﹤0.01% 1516
2020
Q3 		$4.68M Sell
18,824
-328
-2% -$103K ﹤0.01% 1373
2020
Q2 		$6.65M Sell
19,152
-1,251
-6% -$390K ﹤0.01% 1180
2020
Q1 		$5.46M Sell
20,403
-123
-0.6% -$38K ﹤0.01% 1139
2019
Q4 		$6.65M Buy
20,526
+2,559
+14% +$742K ﹤0.01% 1268
2019
Q3 		$4.91M Buy
17,967
+18
+0.1% +$6.6K ﹤0.01% 1400
2019
Q2 		$9.58M Buy
17,949
+430
+2% +$216K 0.01% 1083
2019
Q1 		$8.83M Sell
17,519
-3
-0% -$1.78K 0.01% 1107
2018
Q4 		$8.64M Buy
17,522
+398
+2% +$240K 0.01% 1043
2018
Q3 		$15.7M Sell
17,124
-89
-0.5% -$76K 0.01% 859
2018
Q2 		$12.6M Sell
17,213
-11,963
-41% -$13.8M 0.01% 884
2018
Q1 		$46.5M Buy
29,176
+11,609
+66% +$15M 0.03% 501
2017
Q4 		$15.7M Buy
17,567
+2,151
+14% +$1.27M 0.01% 843
2017
Q3 		$5.55M Hold
15,416
– – ﹤0.01% 1168
2017
Q2 		$4.52M Buy
15,416
+1,474
+11% +$426K ﹤0.01% 1268
2017
Q1 		$4.91M Sell
13,942
-887
-6% -$199K ﹤0.01% 1200
2016
Q4 		$2.73M Sell
14,829
-1,220
-8% -$248K ﹤0.01% 1616
2016
Q3 		$4.14M Hold
16,049
– – ﹤0.01% 1227
2016
Q2 		$3.43M Buy
16,049
+633
+4% +$141K ﹤0.01% 1269
2016
Q1 		$3.18M Sell
15,416
-746
-5% -$143K ﹤0.01% 1282
2015
Q4 		$4.08M Sell
16,162
-74
-0.5% -$15.2K ﹤0.01% 1146
2015
Q3 		$2.67M Sell
16,236
-17,680
-52% -$3.13M ﹤0.01% 1429
2015
Q2 		$6.36M Hold
33,916
– – 0.01% 1019
2015
Q1 		$5.6M Buy
33,916
+12,085
+55% +$2.48M ﹤0.01% 1071
2014
Q4 		$5.08M Sell
21,831
-8,663
-28% -$1.85M ﹤0.01% 1113
2014
Q3 		$5.52M Buy
30,494
+8,513
+39% +$1.63M ﹤0.01% 1050
2014
Q2 		$4.23M Sell
21,981
-5
-0% -$884 ﹤0.01% 1222
2014
Q1 		$4M Sell
21,986
-382
-2% -$75.6K ﹤0.01% 1249
2013
Q4 		$3.81M Hold
22,368
– – ﹤0.01% 1279
2013
Q3 		$3.51M Hold
22,368
– – ﹤0.01% 1290
2013
Q2 		$3.88M Buy
+22,368
New +$3.43M ﹤0.01% 1142

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein's NKTR Position: Q2 2026 in Review

AllianceBernstein opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 36,000 shares worth $2.59M. The stake represents ﹤0.01% of the portfolio and ranks #1893 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in NKTR as recently as Q1 2025.

AllianceBernstein first reported a position in NKTR in Q2 2013 and has held it in 45 quarters since. The position peaked at $46.5M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • AllianceBernstein held 36,000 shares of Nektar Therapeutics worth $2.59M as of Q2 2026.
  • Nektar Therapeutics was a new AllianceBernstein position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1893 holding.
  • AllianceBernstein first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • AllianceBernstein's Nektar Therapeutics position peaked at $46.5M in Q1 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.